Interactive Brokers Advertisement
Home > Boards > US Listed > Medical - Healthcare >

Acasti Pharma, Inc (ACST)

Add ACST Price Alert      Hide Sticky   Hide Intro
Moderator: I.B.Broke
Search This Board: 
Last Post: 11/21/2017 11:57:36 AM - Followers: 40 - Board type: Free - Posts Today: 7

Acasti Pharma is a biopharmaceutical innovator advancing a potentially best-in-class cardiovascular drug, CaPre®, for the treatment of hypertriglyceridemia, a chronic condition affecting an estimated one-third of the U.S. population.

Established in August 2008, Acasti is focused on addressing an important market need for an effective, safe and well-absorbed omega-3 therapeutic that can address a patient’s lipid profile — making a positive impact on the major lipids associated with cardiovascular disease risk.


President and CEO 
Jan D'Alvise


Acasti’s Phase 3-ready investigational candidate CaPre® will be the first pharmaceutical omega-3 product sourced from krill oil. CaPre® has successfully completed phase 1 and 2 trials for the treatment of hypertriglyceridemia, a common metabolic condition characterized by high levels of triglycerides in the blood stream.

The American Heart Association has estimated that one-third of the U.S. population has elevated levels of triglycerides.


CaPre’s concentrated omega-3s from krill oil are absorbed into the body more efficiently than those from fish oils, enhancing bioavailability and providing benefits to a patient’s total lipid profile. That means that CaPre® doesn’t just lower triglycerides; it also has shown in clinical trials to have beneficial effects on “good” and “bad” cholesterol levels that affect heart health.

Laval, Québec, CANADA, Sept. 14, 2016 Acasti Pharma (NASDAQ:ACST TSX-V:APO) today announced that its bridging study for novel drug candidate CaPre® (omega-3 phospholipid) has successfully met its objectives, supporting Acasti’s strategy to pursue the U.S. Food and Drug Administration’s (FDA) 505(b)(2) regulatory pathway for approval. Acasti is developing CaPre for the treatment of patients with severe hypertriglyceridemia, a metabolic condition that contributes to increased risk of cardiovascular disease and pancreatitis. The 505(b)(2) regulatory pathway allows Acasti to streamline the overall development program required to support a New Drug Application (NDA) by relying on the safety data of an approved drug. 

Laval, Québec, CANADA, October 26, 2016 — Acasti Pharma (NASDAQ:ACST TSX-V:APO) today announced that the United States Patent and Trademark Office issued Acasti a patent (U.S. patent no. 9,475,830) directed to a method of treating hypertriglyceridemia by the administration of a concentrated phospholipid composition. 
This newly issued patent expands Acasti’s intellectual property portfolio related to concentrated therapeutic phospholipid omega-3 compositions covering methods for treating or preventing diseases associated with or related to cardiovascular disease. 



Interactive Brokers Advertisement
Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
ACST News: Report of Foreign Issuer (6-k) 11/20/2017 08:02:06 AM
ACST News: Securities Registration (foreign Private Issuer) (f-1/a) 11/16/2017 05:18:24 PM
ACST News: Report of Foreign Issuer (6-k) 11/14/2017 06:07:11 AM
ACST News: Report of Foreign Issuer (6-k) 11/13/2017 05:28:58 PM
ACST News: Report of Foreign Issuer (6-k) 11/07/2017 05:06:37 PM
#292  Sticky Note Acasti Pharma Announces Development and Commercialization Discussions Progres [SMART MONEY] 11/20/17 09:01:30 AM
#316   Will be back in the 2.60 range soon.. leonardo1 11/21/17 11:57:36 AM
#315   Profit taking over? Slowly climbing back up. difumetti 11/21/17 10:02:59 AM
#314   Strong Buy,agreement will be reached n signed.jmhtto ~MulaGreen~ 11/21/17 09:59:06 AM
#313   Seems like it. Let the party begin!!!! $ACST!! I.B.Broke 11/21/17 09:26:12 AM
#312   Ohhhh yes it is.. Lame ppl want in tabuhasna 11/21/17 09:17:25 AM
#311   after closed 3.10 and now trading 2.46, feels [SMART MONEY] 11/21/17 08:42:30 AM
#310   congrats... is that you on the right in your [SMART MONEY] 11/21/17 04:09:11 AM
#309   * * $ACST Video Chart 11-20-17 * * ClayTrader 11/20/17 04:57:51 PM
#308   Fantastic day. I've been accumulating for the last I.B.Broke 11/20/17 04:14:41 PM
#307   What a freakin day!! Held these guys for PhantomCash 11/20/17 04:11:39 PM
#306   Nice close! UP Trend 11/20/17 04:01:34 PM
#305   Yeaaah $3.10 close!!! [SMART MONEY] 11/20/17 04:00:41 PM
#304   go baby!! go>>>> I double up [SMART MONEY] 11/20/17 03:58:29 PM
#303   You better buy on the dip!!! $ACST I.B.Broke 11/20/17 01:41:04 PM
#302   Filled Buy 1000 ACST Limit 2.38 -- -- 11:13:20 11/20/17 [SMART MONEY] 11/20/17 12:55:19 PM
#301   I got in around $2.15. News just difumetti 11/20/17 12:47:55 PM
#300   Multi day run would be sweet at this pace. UP Trend 11/20/17 12:46:34 PM
#299   Here we Go Hie Break run europtiger 11/20/17 12:41:36 PM
#298   Should be Running for a couple days imo europtiger 11/20/17 11:13:27 AM
#297   Grabbed starter on dip as well, great news. UP Trend 11/20/17 11:03:28 AM
#296   Beautiful!! $ACST I.B.Broke 11/20/17 10:57:19 AM
#295   Got me some 2,17 europtiger 11/20/17 10:51:14 AM
#294   buyout soon.... scaptrader1297 11/20/17 10:42:40 AM
#293   thank you fer heads up/ 'Acasti Pharma, mick 11/20/17 09:49:47 AM
#292   Acasti Pharma Announces Development and Commercialization Discussions Progres [SMART MONEY] 11/20/17 09:01:30 AM
#291   Acasti Pharma Announces Dariush Mozaffarian, M.D., Dr.P.H. Principal I.B.Broke 11/07/17 08:28:58 PM
#290   CaPre progression and expected launch schedule I.B.Broke 09/25/17 07:43:57 PM
#289   Acasti reports 1Q loss I.B.Broke 08/15/17 11:43:04 AM
#288   We sustained our positive business performance in the I.B.Broke 08/15/17 11:40:46 AM
#287   Acasti Pharma Reports First Quarter FY 2018 Financial Results I.B.Broke 08/15/17 11:38:32 AM
#286   Vote Recieved in mail vote for Directors and more PJO 07/28/17 02:46:55 PM
#285   Acasti Pharma Inc (ACST) Sees RMI Trending Upward I.B.Broke 07/28/17 10:07:53 AM
#284   Acasti Pharma Announces Issuance of Common Shares in I.B.Broke 07/28/17 10:05:41 AM
#283   CORRECTION: Acasti Pharma Grants Stock Options I.B.Broke 06/16/17 05:52:58 PM
#282   Acasti Pharma Grants Stock Options I.B.Broke 06/15/17 09:02:19 AM
#281   Acasti and CordenPharma look to continuous production for I.B.Broke 06/13/17 08:12:33 PM
#280   Acasti Pharma To Present at Upcoming International Industry Conferences I.B.Broke 06/12/17 12:13:23 PM
#279   Acasti Pharma and CordenPharma Announce Large Scale Production I.B.Broke 05/31/17 07:28:01 PM
#278   Acasti Granted Additional Composition & Use Patents in I.B.Broke 04/25/17 05:42:25 PM
#277   Acasti Pharma to Present CaPre Omega-3 Bridging Study I.B.Broke 04/14/17 09:12:29 PM
#276   Acasti Pharma Provides Update On CaPre Phase 3 I.B.Broke 03/30/17 05:44:39 PM
#275   Phase 3 news PJO 03/30/17 10:21:57 AM
#274   HAYWOOD GEORGE WEAVER has filed a new 13G, wiltonio 03/22/17 04:34:58 PM
#273   Acasti Pharma Forms Scientific Advisory Board and Appoints I.B.Broke 03/08/17 06:25:18 PM
#272   Corporation prepares to advance CaPre®, its krill-based omega-3 I.B.Broke 02/25/17 04:17:09 PM
#271   Acasti Pharma Grants Incentive Stock and Options I.B.Broke 02/25/17 04:15:50 PM
#270   Acasti Pharma Announces Closings of Concurrent Public Offering I.B.Broke 02/24/17 11:27:05 AM
#269   Acasti Pharma Announces Pricing for its Public Offering I.B.Broke 02/13/17 06:59:52 PM
#268   Acasti Pharma Announces Proposed Private Placement of Convertible I.B.Broke 02/02/17 06:52:32 PM
#267   * * $ACST Video Chart 12-23-16 * * ClayTrader 12/23/16 04:22:57 PM